Center for Orphan Drug Research Presents New Topiramate Injection Data
April 8, 2024
Ligand Pharmaceuticals Incorporated has announced that new new data on Captisol-enabled™ Topiramate Injection (IV topiramate) data was presented at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference on Monday, April 8, 2024. The poster was co-authored by Dr. James Cloyd, director of the University of Minnesota’s Center for Orphan Drug Research and graduate student Adeboye Bamgboye.
IV topiramate is a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible.
Ligand Pharmaceuticals has partnered with the University of Minnesota and CURx Pharmaceuticals Inc. in this work.
Media Contacts
Related Stories
Dr. Melanie Nicol, associate professor and director of graduate studies in the Department of Experimental and Clinical Pharmacology (ECP) received a new award of $3 million across the next five years from the National Institutes of Health (NIH).
Debasmita attended the annual Alliance for Nanotechnology in Cancer meeting with Prof. Carston Wagner.
Laura Hirsch received a Bighley Fellowship and Rui Shi received a Rowell Fellowship.